Mablink Bioscience and Emergence Therapeutics Enter into a Licensing Agreement to Develop Antibody Drug Conjugate as a potential cancer therapy
Emergence Therapeutics obtains the rights to develop a novel antibody-drug conjugate using Mablink Bioscience’s proprietary PSARlink™ drug-linker technology Lyon, France & Duisburg, Germany, October 21, 2021 Mablink Bioscience S.A.S. a …